TABLE 2.
dRAST versus reference method for Gram-negative bacteria from prospective clinical blood culture samplesa
| Antibiotic | Total tested | S | I | R | VME (%) | ME (%) | mE (%) | % CA |
|---|---|---|---|---|---|---|---|---|
| Amikacin | 124 | 121 | 3 | 0 | 0 (0.0) | 2 (1.7) | 3 (2.4) | 96.0 |
| Cefotaxime | 119 | 104 | 1 | 14 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 100.0 |
| Ceftazidime | 122 | 106 | 1 | 15 | 0 (0.0) | 3 (2.8) | 4 (3.3) | 94.3 |
| Ciprofloxacin | 124 | 95 | 6 | 23 | 1 (4.3) | 1 (1.1) | 7 (5.6) | 92.7 |
| Gentamicin | 124 | 116 | 1 | 7 | 1 (14.3) | 0 (0.0) | 3 (2.4) | 96.8 |
| Imipenem | 120 | 118 | 2 | 0 | 0 (0.0) | 1 (0.8) | 3 (2.5) | 97.5 |
| Meropenem | 124 | 123 | 1 | 0 | 0 (0.0) | 1 (0.8) | 1 (0.8) | 98.4 |
| Piperacillin/Tazobactam | 122 | 104 | 1 | 17 | 12 (70.6) | 2 (1.9) | 3 (2.5) | 86.1 |
| Trimethoprim/Sulfamethoxazole | 121 | 90 | 0 | 31 | 0 (0.0) | 0 (0.0) | 1 (0.8) | 99.2 |
| ESBL | 109 | 94 | 0 | 15 | 2 (13.3) | 0 (0.0) | 0 (0.0) | 98.2 |
| Overall | 1209 | 1071 | 16 | 122 | 16 (13.1) | 10 (0.9) | 25 (2.1) | 95.9 |
a
S, susceptible; I, intermediate; R, resistant; ESBL, extended spectrum β-lactamase-producing; VME, very major error; ME, major error; mE, minor error; CA, categorical agreement. Percentage VME and ME were calculated based on the number of resistant and susceptible isolates, respectively.